<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia - Taylor-Rowan, M - 2022 | Cochrane Library</title> <meta content="Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia - Taylor-Rowan, M - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015196.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia - Taylor-Rowan, M - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015196.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015196.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia" name="citation_title"/> <meta content="Martin Taylor-Rowan" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Olga Kraia" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Christina Kolliopoulou" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Anna H Noel-Storr" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Ahmed A. Alharthi" name="citation_author"/> <meta content="Umm Al Qura University" name="citation_author_institution"/> <meta content="Amanda J Cross" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Carrie Stewart" name="citation_author"/> <meta content="IAHS, University of Aberdeen" name="citation_author_institution"/> <meta content="Phyo K Myint" name="citation_author"/> <meta content="University of Aberdeen" name="citation_author_institution"/> <meta content="Jenny McCleery" name="citation_author"/> <meta content="Oxford Health NHS Foundation Trust" name="citation_author_institution"/> <meta content="Terry J Quinn" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Terry.Quinn@glasgow.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD015196.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/08/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015196.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015196.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015196.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cholinergic Antagonists [adverse effects]; *Cognitive Dysfunction [chemically induced]; *Dementia [chemically induced]; Prospective Studies; Retrospective Studies" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015196.pub2&amp;doi=10.1002/14651858.CD015196.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015196\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015196\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015196.pub2",title:"Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia",firstPublishedDate:"Aug 22, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015196.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015196.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015196.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015196.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015196.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015196.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015196.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015196.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015196.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015196.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3946 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015196.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-sec-0057"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-sec-0051"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/appendices#CD015196-sec-0061"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Prognosis</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0004">Martin Taylor-Rowan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0005">Olga Kraia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0006">Christina Kolliopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0007">Anna H Noel-Storr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0008">Ahmed A. Alharthi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0009">Amanda J Cross</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0010">Carrie Stewart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0011">Phyo K Myint</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0012">Jenny McCleery</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information#CD015196-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Terry J Quinn</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information/en#CD015196-sec-0070">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 August 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015196.pub2">https://doi.org/10.1002/14651858.CD015196.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015196-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015196-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015196-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015196-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015196-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015196-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015196-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015196-abs-0001" lang="en"> <section id="CD015196-sec-0001"> <h3 class="title" id="CD015196-sec-0001">Background</h3> <p>Medications with anticholinergic properties are commonly prescribed to older adults with a pre‐existing diagnosis of dementia or cognitive impairment. The cumulative anticholinergic effect of all the medications a person takes is referred to as the anticholinergic burden because of its potential to cause adverse effects. It is possible that a high anticholinergic burden may be a risk factor for further cognitive decline or neuropsychiatric disturbances in people with dementia. Neuropsychiatric disturbances are the most frequent complication of dementia that require hospitalisation, accounting for almost half of admissions; hence, identification of modifiable prognostic factors for these outcomes is crucial. There are various scales available to measure anticholinergic burden but agreement between them is often poor. </p> </section> <section id="CD015196-sec-0002"> <h3 class="title" id="CD015196-sec-0002">Objectives</h3> <p>Our primary objective was to assess whether anticholinergic burden, as defined at the level of each individual scale, was a prognostic factor for further cognitive decline or neuropsychiatric disturbances in older adults with pre‐existing diagnoses of dementia or cognitive impairment. Our secondary objective was to investigate whether anticholinergic burden was a prognostic factor for other adverse clinical outcomes, including mortality, impaired physical function, and institutionalisation. </p> </section> <section id="CD015196-sec-0003"> <h3 class="title" id="CD015196-sec-0003">Search methods</h3> <p>We searched these databases from inception to 29 November 2021: MEDLINE OvidSP, Embase OvidSP, PsycINFO OvidSP, CINAHL EBSCOhost, and ISI Web of Science Core Collection on ISI Web of Science. </p> </section> <section id="CD015196-sec-0004"> <h3 class="title" id="CD015196-sec-0004">Selection criteria</h3> <p>We included prospective and retrospective longitudinal cohort and case‐control observational studies, with a minimum of one‐month follow‐up, which examined the association between an anticholinergic burden measurement scale and the above stated adverse clinical outcomes, in older adults with pre‐existing diagnoses of dementia or cognitive impairment.   </p> </section> <section id="CD015196-sec-0005"> <h3 class="title" id="CD015196-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion, and undertook data extraction, risk of bias assessment, and GRADE assessment. We summarised risk associations between anticholinergic burden and all clinical outcomes in a narrative fashion. We also evaluated the risk association between anticholinergic burden and mortality using a random‐effects meta‐analysis.  We established adjusted pooled rates for the anticholinergic cognitive burden (ACB) scale; then, as an exploratory analysis, established pooled rates on the prespecified association across scales.  </p> </section> <section id="CD015196-sec-0006"> <h3 class="title" id="CD015196-sec-0006">Main results</h3> <p>We identified 18 studies that met our inclusion criteria (102,684 older adults). Anticholinergic burden was measured using five distinct measurement scales: 12 studies used the ACB scale; 3 studies used the Anticholinergic Risk Scale (ARS); 1 study used the Anticholinergic Drug Scale (ADS); 1 study used the Anticholinergic Effect on Cognition (AEC) Scale; and 2 studies used a list developed by Tune and Egeli.  </p> <p>Risk associations between anticholinergic burden and adverse clinical outcomes were highly heterogenous. Four out of 10 (40%) studies reported a significantly increased risk of greater long‐term cognitive decline for participants with an anticholinergic burden compared to participants with no or minimal anticholinergic burden. No studies investigated neuropsychiatric disturbance outcomes. One out of four studies (25%) reported a significant association with reduced physical function for participants with an anticholinergic burden versus participants with no or minimal anticholinergic burden. No study (out of one investigating study) reported a significant association between anticholinergic burden and risk of institutionalisation. Six out of 10 studies (60%) found a significantly increased risk of mortality for those with an anticholinergic burden compared to those with no or minimal anticholinergic burden. Pooled analysis of adjusted mortality hazard ratios (HR) measured anticholinergic burden with the ACB scale, and suggested a significantly increased risk of death for those with a high ACB score relative to those with no or minimal ACB scores (HR 1.153, 95% confidence interval (CI) 1.030 to 1.292; 4 studies, 48,663 participants). An exploratory pooled analysis of adjusted mortality HRs across anticholinergic burden scales also suggested a significantly increased risk of death for those with a high anticholinergic burden (HR 1.102, 95% CI 1.044 to 1.163; 6 studies, 68,381 participants).   </p> <p>Overall GRADE evaluation of results found low‐ or very low‐certainty evidence for all outcomes.  </p> </section> <section id="CD015196-sec-0007"> <h3 class="title" id="CD015196-sec-0007">Authors' conclusions</h3> <p>There is low‐certainty evidence that older adults with dementia or cognitive impairment who have a significant anticholinergic burden may be at increased risk of death. No firm conclusions can be drawn for risk of accelerated cognitive decline, neuropsychiatric disturbances, decline in physical function, or institutionalisation.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015196-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015196-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015196-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015196-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015196-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015196-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015196-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015196-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015196-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015196-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015196-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015196-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015196-abs-0002" lang="en"> <h3>The impact of cumulative medications with anticholinergic effects on future adverse clinical outcomes in people with dementia </h3> <p><b>Key messages</b> </p> <p>Anticholinergic medicines may increase the risk of death in older adults who have dementia.  However, the evidence is low certainty, and we cannot say for certain if the anticholinergic medicines cause death, or if they are simply more likely to be used by people who are already at an increased risk of dying due to ongoing health problems.  </p> <p>We cannot draw firm conclusions for the risk that anticholinergic medicines pose to the development of other undesirable clinical outcomes, such as further deterioration of memory and thinking, or behavioural and psychological issues.  More research is needed to establish whether anticholinergic medicines cause unintended problems for older adults who have dementia. </p> <p><b>What are anticholinergic medicines?</b> </p> <p>Medicines can be classified by their ability to block the action of a chemical signalling system in the body, called the cholinergic system. Medicines that do this are said to have anticholinergic effects, and therefore, are referred to as anticholinergic medicines. </p> <p><b>What did we want to find out? </b> </p> <p>Anticholinergic medicines are commonly used to treat a number of medical conditions that people with dementia frequently experience. Typical examples are medicines used to treat urinary tract infections or episodes of agitation. However, because the cholinergic system in the brain plays an important role in learning, memory, and emotional regulation, there are theoretical reasons to believe that the use of anticholinergic medicines may unintentionally exacerbate psychological problems in this population. In this review, we investigated the link between anticholinergic medicines and future occurrence of undesirable clinical outcomes in people with dementia.  </p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at the link between anticholinergic medicines and a range of clinical outcomes in people with dementia. We compared and summarised the results of identified studies and rated our confidence in the evidence, based on factors, such as study methods and sizes.  </p> <p><b>What did we find?</b> </p> <p>We found a total of 18 studies, involving 102,684 adults aged 50 years or more, who had issues with memory and thinking. We found that the evidence was highly inconsistent regarding the link between anticholinergic medicines and increased issues with memory and thinking in people with dementia. There were no studies that investigated the link between anticholinergic medicines and frequency of behavioural disturbances. Therefore, we could not draw any conclusions about whether anticholinergic medicines cause issues with memory and thinking, or behavioural disturbances in this population. However, we did find there was a more consistent link between anticholinergic medicines and the risk of death. Those who were taking anticholinergic medicines had a 15% higher risk of dying than those who were not taking anticholinergic medicines.   </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The available evidence is very low certainty because of the inconsistency of study results, and the lack of control for health conditions that could be linked with both the clinical outcomes and the prescribing of anticholinergic medicines themselves. It is possible that anticholinergic medicines may not actually cause death, but are simply more likely to be given to people who are already at an increased risk of dying due to ongoing health problems.   </p> <p><b>How up to date is this evidence?</b> </p> <p>We searched for studies published up to 29 November 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015196-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015196-sec-0057"></div> <section id="CD015196-sec-0058"> <h3 class="title" id="CD015196-sec-0058">Implications for practice</h3> <p>The inconclusive evidence warrants the need for caution when prescribing anticholinergic medications in a cognitively impaired population. While we cannot be certain of any causal relationship, most studies found an association with a higher risk of mortality for people with a high anticholinergic burden, and adverse associations were observed for all clinical outcomes, bar institutionalisation, by at least one study.  </p> </section> <section id="CD015196-sec-0059"> <h3 class="title" id="CD015196-sec-0059">Implications for research</h3> <p>The lack of studies investigating neuropsychiatric outcomes is a major gap in the literature. Psychological and behavioural disturbances are main causes of hospitalisation in the dementia population (<a href="./references#CD015196-bbs2-0083" title="SotoME , AndrieuS , VillarsH , SecherM , GardetteV , ColeyN , et al. Improving care of older adults with dementia: description of 6299 hospitalizations over 11 years in a special acute care unit. Journal of the American Directors Association2012;13(5):486.e1-6.">Soto 2012</a>); hence, identification of modifiable variables that influence their occurrence is extremely important. It is biologically plausible that anticholinergic drugs could induce behavioural disturbances in people with dementia (Cancelli 2009), and there is evidence from interventional studies that a reduction of anticholinergic burden diminishes the occurrence of neuropsychiatric disturbance (<a href="./references#CD015196-bbs2-0068" title="JaïdiY , NonnonhouV , KanagaratnamL , BertholonLA , BadrS , NoëlV , et al. Reduction of the anticholinergic burden makes it possible to decrease behavioral and psychological symptoms of dementia. American Journal of Geriatric Psychiatry2018;26(3):280-8. [PMID: 28890165]">Jaïdi 2018</a>; <a href="./references#CD015196-bbs2-0069" title="JaïdiY , GuilloteauA , NonnonhouV , BertholonLA , BadrS , MorroneI , et al. Threshold for a reduction in anticholinergic burden to decrease behavioral and psychological symptoms of dementia. Journal of the American Medical Directors Association2019;20(2):159-64. [PMID: 30503588]">Jaïdi 2019</a>). Thus, it would be reasonable to expect a prognostic association to exist between anticholinergic burden and neuropsychiatric outcomes. Therefore, high quality studies to investigate whether such an association exists, and in what circumstances, would be valuable.  </p> <p>Our review highlighted the considerable number of variables that could potentially influence the relationship between anticholinergic burden and clinical outcomes in a cognitively impaired population. At present, most studies do a poor job of controlling for and reporting details of these variables. This may reflect an over‐reliance upon pre‐existing datasets that were not designed to investigate the association between anticholinergic burden and clinical outcomes. We would encourage more prospectively designed research studies in this area, as this would enable researchers to tailor important design features to the specific requirements of the area. Our <a href="./references#CD015196-sec-0076" title="">Characteristics of included studies</a> section presents a list of potentially important variables, and we would recommend that future investigators consider these when designing studies, and record them in detail, whenever possible.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015196-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015196-sec-0008"></div> <div class="table" id="CD015196-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>‐Risk of cognitive decline or neuropsychiatric outcomes in people with dementia for those with an anticholinergic burden compared to those with no or minimal anticholinergic burden</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> older adults with cognitive impairment at baseline </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention:</b> anticholinergic burden </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Comparison:</b> no or minimal anticholinergic burden </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcomes:</b> cognitive decline (multi‐domain) or neuropsychiatric disturbances </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Timing:</b> prognostic factors measured at baseline; outcomes obtained at a minimum of 1‐month follow‐up via longitudinal, observational cohort or case‐control study design </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Setting:</b> mixed (care homes, community, hospitals) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Relative effect (95%CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>No. of participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive decline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18213</p> <p>(10)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝  </p> <p>Very low<sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies were too heterogeneous to pool.  The majority of studies did not identify a significantly increased risk for those with an anticholinergic burden compared to those with no or minimal burden.  However, the inconsistency and high risk of bias of the available evidence means no firm conclusions can be drawn.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies assessed this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>AChEI:</b> acetylcholinesterase inhibitor; <b>CI:</b> confidence interval; <b>NA:</b> not applicable </p> <p><b>GRADE Working Group grades of evidence </b> </p> <p><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect </p> <p><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate </p> <p><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate </p> <p><b>Very low certainty:</b> we are very uncertain about the estimate </p> <p><sup>a</sup><a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a><br/><sup>b</sup>Most studies were at high risk of bias; downgraded 2 levels<br/><sup>c</sup>Results and measurement methods across studies werehighly heterogeneous; downgraded 2 levels<br/><sup>d</sup>Most studies conducted in Alzheimer disease population only, or dementia population who were also on AChEIs; downgraded 2 levels<br/><sup>e</sup>We were unable to formally investigate publication bias via a funnel plot; however, publication bias is assumed within this literature; downgraded 1 level </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015196-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015196-sec-0009"></div> <section id="CD015196-sec-0010"> <h3 class="title" id="CD015196-sec-0010">Description of the condition</h3> <p>Cognition (or cognitive function) is the mental process of acquiring knowledge and understanding through experience, senses, and thought. It includes the domains of memory, language, attention, executive functioning, and visuospatial processing. Cognitive impairment is the disruption of functioning of any one of these domains. Cognitive function may be assessed in detail, using a battery of neuropsychological tests covering multiple domains; although in clinical practice, brief assessment tools, such as the Mini Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA), are often used (<a href="./references#CD015196-bbs2-0059" title='FolsteinMF , FolsteinSE , McHughPR . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189-98.'>Folstein 1975</a>; <a href="./references#CD015196-bbs2-0075" title="NasreddineZS , PhillipsNA , BédirianV , CharbonneauS , WhiteheadV , CollinI , et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatric Society2005;53:695-9.">Nasreddine 2005</a>). </p> <p>Dementia is a syndrome of decline in cognitive function beyond that expected from normal ageing, to an extent that interferes with usual functioning. It may affect memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. There are a variety of internationally accepted diagnostic criteria for dementia, the most widely used of which are included in the World Health Organization International Classification of Diseases (ICD) and the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM). The most recent iteration of the DSM (DSM‐5) refers to 'major neurocognitive disorder' instead of dementia.  </p> <p>The labels of 'dementia' or 'major neurocognitive disorder' encompass a variety of pathologies, with specific diagnostic criteria also available for pathologically defined dementia subtypes, such as the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA) criteria for dementia due to Alzheimer's disease (<a href="./references#CD015196-bbs2-0072" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34:939-44.">McKhann 1984</a>; <a href="./references#CD015196-bbs2-0074" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , Jack CR Jr, KawasCH , et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer's &amp; Dementia2011;7:263-9.">McKhann 2011</a>); McKeith criteria for Lewy body dementia (<a href="./references#CD015196-bbs2-0071" title="McKeithIG , DicksonDW , LoweJ , EmreM , O'BrienJT , FeldmanH , et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology2005;65:1863-72.">McKeith 2005</a>); Lund criteria for frontotemporal dementias (<a href="./references#CD015196-bbs2-0073" title="McKhannGM , AlbertMS , GrossmanM , MillerB , DicksonD , TrojanowskiJQ . Clinical and pathological diagnosis of frontotemporal dementia: report of the Work group on frontotemporal dementia and Pick's disease. Archives of Neurology2001;58:1803-9.">McKhann 2001</a>); and the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria for vascular dementia (<a href="./references#CD015196-bbs2-0080" title="RománGC , TatemichiTK , ErkinjuttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology1993;43:250-60.">Román 1993</a>). </p> <p>An individual may experience a decline in cognition that is not enough to merit a label of dementia, but that is more than would be expected as part of ageing. An objective cognitive impairment that is not severe enough to have a significant impact on daily activities is referred to as a mild cognitive impairment (MCI). This is a risk factor for future dementia, as one in five may go on to develop dementia within five years (<a href="./references#CD015196-bbs2-0077" title="PetersenRC , StevensJC , GanguliM , TangalosEG , CummingsJL , DeKoskyST . Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality standards subcommittee of the American academy of neurology. Neurology2001;56:1133-42.">Petersen 2001</a>). </p> <p>Dementia is a major public health issue. There are currently more than 40 million people worldwide with dementia due to Alzheimer's disease – the most common subtype – and this number is projected to increase to more than 100 million by 2050 (<a href="./references#CD015196-bbs2-0078" title="PrinceM , Comas-HerreraA , KnappM , GuerchetM , KaragiannidouM . Improving healthcare for people living with dementia: coverage, quality and costs now and in the future. www.alzint.org/resource/world-alzheimer-report-2016/  (accessed prior to 27 April 2021).">Prince 2016</a>). </p> <p>As cognitive functioning declines, people’s ability to live independently also decreases. In turn, this increases caregiver burden, healthcare support requirements, and institutionalisation. In addition, neuropsychiatric disturbances are a common consequence of declining cognition. Up to 90% of people with Alzheimer’s disease experience neuropsychiatric symptoms, such as mood disturbance, depression, agitation, anxiety, sleep disorder, psychosis, hallucinations, and delusions (<a href="./references#CD015196-bbs2-0084" title="SteinbergM , ShaoH , ZandiP , LyketsosCG , Welsh-BohmerKA , NortonMC , et al, Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County study. International Journal of Geriatric Psychiatry2008;23:170-7.">Steinberg 2008</a>). Occurrence of neuropsychiatric disturbances are the most frequent complication of dementia that require hospitalisation, accounting for 49.4% of admissions (<a href="./references#CD015196-bbs2-0083" title="SotoME , AndrieuS , VillarsH , SecherM , GardetteV , ColeyN , et al. Improving care of older adults with dementia: description of 6299 hospitalizations over 11 years in a special acute care unit. Journal of the American Directors Association2012;13(5):486.e1-6.">Soto 2012</a>). </p> <p>Some prognostic factors, such as type of dementia and number of comorbidities, can predict more rapid cognitive decline or increased neuropsychiatric disturbances in people with dementia (<a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>). Identification of prognostic factors can assist healthcare professionals to predict outcomes for people with MCI or dementia, provide prognostic information to people with dementia and their families, and help policymakers to plan for future population healthcare needs. If these prognostic factors are modifiable, they serve as potential targets to reduce the rate of decline, and frequency or severity (or both) of neuropsychiatric disturbances in people with these cognitive syndromes. </p> </section> <section id="CD015196-sec-0011"> <h3 class="title" id="CD015196-sec-0011">Description of the prognostic factor</h3> <p>A prognostic factor is any measure that is associated with a future clinical outcome. The prognostic factor of interest for this review is anticholinergic burden from medication use. </p> <p>People with dementia are commonly prescribed medications that have antagonist activity at acetylcholine receptors, known as anticholinergic medications. Prevalence varies internationally and by setting; however, example estimates suggest around 23.3% of community‐based people with dementia in the USA, 11.7% of memory clinic attendees in Australia, and 37.9% of 'Psychiatry of Later Life' service attendees in Ireland are reported to be taking clinically significant anticholinergic medications (<a href="./references#CD015196-bbs2-0058" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , IlomakiJ , et al. Potentially inappropriate medications and anticholinergic burden in older people attending memory clinics in Australia. Drugs &amp; Aging2016;33(1):37-44.">Cross 2016</a>; Sura 2013; <a href="./references#CD015196-bbs2-0087" title="VaughanRM , FlynnR , GreeneN . Anticholinergic burden of patients with dementia attending a Psychiatry of Later Life service. Irish Journal of Psychological Medicine 2019 May 21 [Epub ahead of print]. [DOI: 10.1017/ipm.2019.20]">Vaughan 2019</a>). Some medications, such as oxybutynin (for overactive bladder), exert their intended action through their anticholinergic activity. For other medications, such as amitriptyline for depression, anticholinergic activity is probably incidental to their intended mechanism of action. The accumulation of medications with anticholinergic properties is referred to as the anticholinergic burden.  </p> <p>Anticholinergics block the binding of acetylcholine to cholinergic receptors in the brain and elsewhere in the body. In the brain, acetylcholine is a neurotransmitter that plays a major role in numerous functions, including cognition, behaviour, and emotion. As such, anticholinergics are hypothesised to cause disruption to cognitive functioning and increase neuropsychiatric disturbance, with greater anticholinergic burden causing greater disruption. </p> <section id="CD015196-sec-0012"> <h4 class="title">Measures of anticholinergic burden</h4> <p>Anticholinergic burden can be measured using a variety of approaches.  Serum radioreceptor anticholinergic activity assay (SAA) is often considered to be a gold standard for measuring peripheral anticholinergic burden; however, it has limited clinical utility and is a poor predictor of effects on the central nervous system (<a href="./references#CD015196-bbs2-0081" title="SalahudeenMS , Chyou T-Y, NishtalaPS . Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature. PLoS One2016;11(3):e0151084. [DOI: 10.1371/ journal.pone.0151084]">Salahudeen 2016</a>). Alternative (non‐SAA) anticholinergic burden measures generally use a person's medication list and assign a score to certain medications. A cumulative total, based on all prescribed medications, is then calculated. There is no consensus on which non‐SAA anticholinergic burden measure provides the most accurate and clinically useful prognostic information. Although these measures should be similar, overlap is limited; they include different medications and assign differing scores to these medications. Scales measuring anticholinergic burden have been developed using a variety of methodologies. For instance, the Drug Burden Index (DBI) measures anticholinergic burden according to pharmacological first‐principles of dose‐response (i.e. through an understanding of the pharmacokinetics and pharmacodynamics of the drug class (<a href="./references#CD015196-bbs2-0065" title="HilmerSN . Calculating and using the drug burden index score in research and practice. Expert Review of Clinical Pharmacology2018;11(11):1053-5. [PMID: 10.1080/17512433.2018.1528145]">Hilmer 2018</a>)); some scales use a literature review, or incorporate expert clinical opinion (or both) in their development, and are designed to measure both central and peripheral anticholinergic effects; while others focus on serum radioreceptor anticholinergic activity assays or muscarinic receptor affinity measurements, and may only capture peripheral anticholinergic effects (<a href="./references#CD015196-bbs2-0070" title="MayerT , HaefeliWE , SeidlingHM . Different methods, different results—how do available methods link a patient’s anticholinergic load with adverse outcomes?European Journal of Clinical Pharmacology2015;71(11):1299–314. [DOI: 10.1007/s00228-015-1932-x]">Mayer 2015</a>). Therefore, when reviewing the literature about the prognostic impact of anticholinergic medications, it is important to estimate effects at the level of the individual scale, as well as across different scales. </p> <p>In order to determine if anticholinergic burden measures can be used to predict increased cognitive decline or neuropsychiatric disturbance in people with MCI or dementia, a comprehensive assessment of the available literature is needed. The relationship between anticholinergic burden and outcome may vary with multiple factors, including the clinical and demographic make‐up of the population being investigated (e.g. care‐home populations versus non‐care‐home populations), or the duration of drug exposure. The severity and subtype of dementia may also be important; for instance, the cholinergic hypothesis proposes that disruption of cholinergic neurotransmission may play an important role in the cognitive deterioration seen in Alzheimer's disease (<a href="./references#CD015196-bbs2-0060" title="FrancisPT , PalmerAM , SnapeM , WilcockGK . The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery &amp; Psychiatry1999;66(2):137-47.">Francis 1999</a>); hence, prolonged use of anticholinergic medications may affect the rate of cognitive deterioration more substantially in people with Alzheimer's dementia than in other dementia subtypes. If anticholinergic burden is a prognostic factor, then the strength of the association and the quality of the supporting evidence should also be described. Looking at the prognostic properties of each anticholinergic burden measure may assist in choosing a preferred scale for anticholinergic burden assessment in clinical practice. </p> </section> </section> <section id="CD015196-sec-0013"> <h3 class="title" id="CD015196-sec-0013">Why is it important to do this review?</h3> <p>This review is intended to serve as a companion to the recently published Cochrane Review on anticholinergic burden as a prognostic factor for development of cognitive decline or dementia in cognitively healthy older adults, as associations between anticholinergic burden and cognitive decline in cognitively healthy older adults have been consistently reported (<a href="./references#CD015196-bbs2-0085" title="Taylor-RowanM , EdwardsS , Noel-StorrAH , McCleeryJ , MyintPK , SoizaR , et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013540. [DOI: 10.1002/14651858.CD013540.pub2]">Taylor‐Rowan 2021</a>). Drugs with anticholinergic properties are hypothesised to cause further disruption to cognition and increased occurrence of neuropsychiatric disturbance in those with MCI and dementia. However, to date, the evidence to support this hypothesis has been mixed (<a href="./references#CD015196-bbs2-0088" title="WangK , AlanJ , PageAT , DimopolousE , Etherton-BeerC . Anticholinergics and clinical outcomes amongst people with pre-existing dementia: a systematic review. Maturitas2021;151:1-14.">Wang 2021</a>). Consequently, there is uncertainty regarding the clinical value of measuring anticholinergic burden within an already cognitively impaired population. In this review, we aimed to estimate the prognostic utility (adjusted and unadjusted) of different anticholinergic burden measures for predicting cognitive decline or neuropsychiatric disturbances in people with MCI or dementia, and to assess the certainty of the supporting evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015196-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015196-sec-0014"></div> <section id="CD015196-sec-0015"> <h3 class="title" id="CD015196-sec-0015">Primary objective</h3> <p>To assess whether anticholinergic burden, at the level of individual measurement scales, is a prognostic factor for further cognitive decline or neuropsychiatric disturbances in people with mild cognitive impairment (MCI) or dementia.  </p> </section> <section id="CD015196-sec-0016"> <h3 class="title" id="CD015196-sec-0016">Secondary objective</h3> <p> <ul id="CD015196-list-0001"> <li> <p>To compare the prognostic validity of different anticholinergic burden scales</p> </li> <li> <p>To examine the effect of type of dementia and severity of dementia on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances </p> </li> <li> <p>To examine the effect of setting (care home versus non‐care home) on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances </p> </li> <li> <p>To examine whether anticholinergic burden is a prognostic factor for other clinical outcomes in people with MCI or dementia </p> </li> </ul> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015196-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015196-sec-0017"></div> <p>We followed best practice in design, conduct, and reporting for our prognosis review, as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015196-bbs2-0064" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). The review was supported by the Cochrane Prognostic Methods Group, partners within the Cochrane Mental Health and Neuroscience Network, and the UK National Institute for Health Research Complex Reviews Support Unit (NIHR CRSU). </p> <p>We used the PICOT (Patient/Problem; Intervention; Comparison; Outcome; Timing) system to design our review question (<a href="./references#CD015196-bbs2-0082" title="SchardtC , AdamsMB , OwensT , KeitzS , FonteloP . Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Medical Informatics and Decision Making2007;15:7-16.">Schardt 2007</a>; <a href="#CD015196-tbl-0002">Table 1</a>). As recommended by the Cochrane Prognosis Methods Group, we followed guidelines suggested by <a href="./references#CD015196-bbs2-0079" title="RileyRD , MoonsKG , SnellKI , EnsorJ , HooKL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;30:k4597.">Riley 2019</a>, to ensure that our review was designed, conducted, and reported in keeping with best practice recommendations. </p> <div class="table" id="CD015196-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient/Problem; Intervention; Comparison; Outcome; Timing (PICOTS)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Older adults (mean age ≥ 50 years) with prior cognitive impairment, MCI, dementia, or AChE use at baseline </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic burden, measured by any validated ordinal anticholinergic burden scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator prognostic factors (covariates of interest)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age, sex, comorbidity, and AChE use</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive decline (multidomain) or neuropsychiatric disturbances</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Timing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prognostic factors should be measured at baseline. Outcomes should be obtained at a minimum of 1‐month follow‐up via longitudinal, observational cohort/case‐control study design </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruitment from primary, secondary, or community, or care‐home settings</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AChE: anticholinesterase inhibitor</p> <p>MCI: mild cognitive impairment</p> </div> </div> <section id="CD015196-sec-0018"> <h3 class="title" id="CD015196-sec-0018">Criteria for considering studies for this review</h3> <section id="CD015196-sec-0019"> <h4 class="title">Types of studies</h4> <p>We included prospective and retrospective longitudinal cohort and case‐control observational studies. We did not include cross‐sectional studies, as it is not possible to determine prognosis from this design. We did not include prospective case studies, defined here as having fewer than 20 participants. We excluded studies that were published only as abstracts or posters at conferences, as these have not undergone stringent peer review. Languages deemed viable for translation were Greek, French, Spanish, and Dutch.  </p> </section> <section id="CD015196-sec-0020"> <h4 class="title">Types of participants</h4> <p>We included any studies that recruited middle‐aged and older adults (defined as mean age 50 years or older) who, at the time of recruitment and the time of application of the anticholinergic burden measure, had either a known diagnosis of mild cognitive impairment (MCI) or dementia established by a medical practitioner, cognitive impairment established via a cut‐off on a formal cognitive assessment, or were taking cholinesterase inhibitor drugs. For studies in which a mixed population was recruited, we only included the study if the prevalence of dementia or MCI was more than 70%. </p> <p>We made no restrictions based on comorbidity or polypharmacy, but recorded these factors in our data extraction. We assessed whether acetylcholinesterase (AChE) inhibitor use was measured, and considered any potential impact of this in our risk of bias assessment. We included studies conducted in specific population subgroups, such as Parkinson's disease, schizophrenia, or stroke, provided they met our other inclusion criteria. </p> <p>We included studies conducted in all settings. People recruited in various settings (e.g. care home versus community care) may differ in important demographics (e.g. mean age, dementia severity, clinical or lifestyle factors) that could alter the strength of the association between anticholinergic burden and cognitive decline or neuropsychiatric disturbance. If a study was conducted in a care‐home setting, but did not report numbers with previous MCI or dementia, we included the study in the review but removed it via a sensitivity analysis, as required. </p> </section> <section id="CD015196-sec-0021"> <h4 class="title">Index prognostic factor</h4> <p>The prognostic factor of interest was anticholinergic burden from medications. We included any study describing use of a scale that purports to measure cumulative exposure to medications with anticholinergic properties. Scales did not need to be described as validated for prediction of cognitive outcomes. Previously identified scales are listed in <a href="./appendices#CD015196-sec-0062">Appendix 1</a>. </p> <p>We did not choose a particular measure of primary interest, as there is no consensus on the preferred measure, and there is substantial heterogeneity in clinical practice. However, when the Drug Burden Index (DBI) scale was used, we only included data if anticholinergic burden data were reported separately.  </p> <p>Due to our expectation of a relatively sparse literature, we did not exclude studies that simply used a dichotomised present/absent method to investigate the association between anticholinergic medication use and risk of cognitive decline or neuropsychiatric disturbance. However, as severity of anticholinergic burden may play an important role in identifying any association, we considered the potential impact of this approach in our risk of bias assessment. </p> <p>We did not include studies that only measured anticholinergic burden via serum radioreceptor assay (SAA) levels, as this has limited clinical applicability. </p> </section> <section id="CD015196-sec-0022"> <h4 class="title">Comparator prognostic factors</h4> <p>We were interested in the value of anticholinergic burden as a prognostic factor, over and above other prognostic factors that may be common in this population. Hence, while we included studies that only assessed the unadjusted anticholinergic burden prognosis, we also evaluated the prognostic effect of anticholinergic burden after adjustment for core variables, identified as fundamental to the putative link between anticholinergic burden and further cognitive decline or neuropsychiatric disturbance in people with MCI or dementia. We selected these variables on the basis of a Delphi discussion between the review authors and a wider multicentre collaborative, working in the field of anticholinergic burden research (<a href="./appendices#CD015196-sec-0063">Appendix 2</a>). The chosen core variables were age, sex, comorbidities, and use of AChE inhibitors (N.B. the use of AChE inhibitors was only considered to be a core variable for cognitive outcomes).  </p> <p>We assessed use of additional adjustments in our risk of bias assessment.</p> </section> <section id="CD015196-sec-0023"> <h4 class="title">Outcome measures</h4> <section id="CD015196-sec-0024"> <h5 class="title">Primary outcomes</h5> <p>We included any study that assessed cognitive decline (i.e. change on a measure of cognitive function) or neuropsychiatric disturbance (defined as stressed and distressed behaviours, such as those measured via the Neuropsychiatric Inventory) as an outcome. In the case of people with MCI, we also included studies that assessed incident dementia as an outcome. For the outcome of cognitive decline, we accepted any multi‐domain cognitive assessment tool that was validated for the direct assessment of cognition.  We did not include papers that only measured a single cognitive domain. We only included primary outcomes in our summary of findings table. </p> </section> <section id="CD015196-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p>We also included studies that assessed risk of mortality, decline in physical functioning, and institutionalisation, defined as admission to a care home, in people with pre‐existing cognitive impairment. </p> </section> <section id="CD015196-sec-0026"> <h5 class="title">Timing </h5> <p>On the basis that anticholinergic effects on cognition or neuropsychiatric disturbance may be more rapid in a dementia population than in a cognitively unimpaired population, we accepted assessment for cognitive decline or neuropsychiatric disturbance at one month or longer following baseline anticholinergic burden assessment. We evaluated the risk of reverse causality, based on the duration of follow‐up in our risk of bias assessment. </p> </section> </section> </section> <section id="CD015196-sec-0027"> <h3 class="title" id="CD015196-sec-0027">Search methods for identification of studies</h3> <section id="CD015196-sec-0028"> <h4 class="title">Electronic searches</h4> <p>As reporting of prognostic factor studies is variable, it can be challenging to identify all relevant studies. We adopted the procedure proposed by <a href="./references#CD015196-bbs2-0061" title="GeersingGJ , BouwmeesterW , ZuithoFP , SpijkerR , LeeflangM , MoonsKG . Search filters for finding prognostic and diagnostic prediction studies in MEDLINE to enhance systematic reviews. PLoS One2012;7:e32844.">Geersing 2012</a> to maximise our ability to identify relevant prognostic studies. Specifically, as we searched for one prognostic factor, we did not adopt any specific search filter, but instead, adopted a search that combined our prognostic factor (anticholinergic burden) with the population of interest (people with MCI or dementia). </p> <p>We searched the following databases: MEDLINE OvidSP (1946 to 29 Nov 2021), Embase OvidSP (1974 to 29 Nov 2021), PsycINFO OvidSP (1806 to 29 Nov 2021), CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature; 1950 to 29 Nov 2021), and ISI Web of Science Core Collection ISI Web of Science (1928 to 29 Nov 2021; <a href="./appendices#CD015196-sec-0064">Appendix 3</a>). We did not apply any language restrictions in our primary search, although at title selection, studies that could not be translated into English by the review authors were excluded.   </p> </section> <section id="CD015196-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We supplemented this with handsearches of references of all included studies and identified systematic reviews. </p> </section> </section> <section id="CD015196-sec-0030"> <h3 class="title" id="CD015196-sec-0030">Data collection and analysis</h3> <section id="CD015196-sec-0031"> <h4 class="title">Selection of studies</h4> <p>We used Covidence systematic review software to identify relevant studies (<a href="./references#CD015196-bbs2-0057" title="Covidence. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). The Dementia and Cognitive Improvement Group's Information Specialist performed a 'first pass' screen to remove clearly irrelevant titles.  </p> <p>Three review authors (AA, OK, and CK) independently screened studies identified via our search methods. They screened the titles and abstracts first, then accessed the full text of potentially relevant studies to determine if the study met our inclusion criteria. In cases of disagreement, a fourth review author (MT) acted as arbiter, and made the final decision on study inclusion or exclusion. </p> </section> <section id="CD015196-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (OK and CK) independently extracted the data to a piloted pro forma, based on the CHARMS‐PF (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies, adapted for prognostic factors) template (<a href="./references#CD015196-bbs2-0079" title="RileyRD , MoonsKG , SnellKI , EnsorJ , HooKL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;30:k4597.">Riley 2019</a>). We contacted authors for missing data when required. We selected two studies to trial our data extraction pro forma (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>). We extracted all data onto a standard form (<a href="./appendices#CD015196-sec-0065">Appendix 4</a>). </p> </section> <section id="CD015196-sec-0033"> <h4 class="title">Assessment of methodological quality</h4> <p>Two review authors (OK and CK) independently used the QUIPS (Quality in Prognosis Studies) checklist to assess the included studies across the domains of: study participation; study attrition; prognostic factor measurement; outcome measurement; adjustment for covariates; reverse causation; statistical analyses; and reporting (<a href="./references#CD015196-bbs2-0062" title="HaydenJA , van derWindtDA , CartwrightJL , CôtéP , BombardierC . Assessing bias in studies of prognostic factors. Annals of International Medicine2012;158(4):280-6.">Hayden 2012</a>). A third review author (MT) evaluated all risk of bias estimates and assigned a final rating. We used the QUIPS anchoring statements, but modified the content to suit our review topic, based on consensus within the review team.  </p> <p>We judged each domain as low risk of bias, unclear risk of bias, or high risk of bias (<a href="./appendices#CD015196-sec-0066">Appendix 5</a>). In cases of uncertainty, we contacted original study authors for clarification, when possible. </p> </section> <section id="CD015196-sec-0034"> <h4 class="title">Discussing reporting deficiencies </h4> <p>Prognosis research is frequently confounded by poor reporting and possible publication bias. We supplemented our risk of bias assessment with a narrative discussion of reporting issues, highlighting when missing information may have affected results. Prognostic factor studies often do not register protocols, increasing the risk that not all studies (published and unpublished) can be identified, and there is a risk of small study effects (in which smaller studies with higher odds ratios (ORs) are more likely to be published than smaller studies with non‐significant ORs), which can bias meta‐analyses (<a href="./references#CD015196-bbs2-0076" title="PeatG , RileyRD , CroftP , MorleyKI , KyzasPA , MoonsKG , et al, PROGRESS Group  . Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. PLoS Medicine2014;11(7):e1001671.">Peat 2014</a>; <a href="./references#CD015196-bbs2-0079" title="RileyRD , MoonsKG , SnellKI , EnsorJ , HooKL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;30:k4597.">Riley 2019</a>). We used sensitive search filters for the population (people with MCI or dementia) and the prognostic factor (anticholinergic burden), without any specific filter for prognostic research to increase retrieval. </p> </section> <section id="CD015196-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We evaluated risk of future adverse clinical outcomes narratively, summarising the number and details of studies reporting significant and non‐significant associations for all outcomes of interest. A significant effect was defined as confidence intervals (CI) that did not cross 1.0, or a P value &lt; 0.05, or both. We used a random‐effects model for the meta‐analysis to investigate risk of future mortality. Specifically, we pooled fully adjusted hazard ratio (HR) data, provided that at least age, sex, and comorbidities were controlled for.  We initially pooled hazard ratio data for the Anticholinergic Cognitive Burden (ACB) tool individually; then, as an exploratory analysis, we pooled across all scales. Our meta‐analysis compared participants with moderate or high anticholinergic burden against those with no or low burden, depending on the type of comparison that was reported within a given study. Low users were defined as those with a cumulative score of 1 on an anticholinergic scale; moderate users were defined as those with a cumulative score of 2 on an anticholinergic scale; high users were defined as those with a cumulative anticholinergic scale score of 3 or above. </p> <p>We used Comprehensive Meta‐Analysis software to conduct all meta‐analyses (<a href="./references#CD015196-bbs2-0056" title="Comprehensive Meta-Analysis . BorensteinM , HedgesL , HigginsJ , RothsteinH , Version 3. Englewood (NJ): Biostat Inc. , 2013. Available from www.meta-analysis.com/.">CMA 2013</a>). </p> </section> <section id="CD015196-sec-0036"> <h4 class="title">Investigation and description of heterogeneity</h4> <p>We described heterogeneity narratively, based on the consistency and magnitude of the association between anticholinergic burden and cognitive decline or neuropsychiatric disturbance; measurement of the prognostic factor; outcome measurement and definition; and study design. We did not use the I<sup>2</sup> statistic in our evaluation of heterogeneity. In prognosis research, individual studies often have large sample sizes, resulting in narrow confidence intervals; this can cause high I<sup>2</sup> values even if inconsistency between studies is moderate (<a href="./references#CD015196-bbs2-0067" title="IorioA , SpencerFA , FalavignaM , AlbaC , LangE , BurnandB , et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ2015;350:h870.">Iorio 2015</a>). </p> </section> <section id="CD015196-sec-0037"> <h4 class="title">Grading the evidence</h4> <p>We used the GRADE approach to evaluate our overall confidence in the results. We adapted the GRADE approach to suit prognosis research, using methods consistent with  <a href="./references#CD015196-bbs2-0066" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71.">Huguet 2013</a>. Specifically, we evaluated reported evidence in the following eight areas.  </p> <p><b>Phase of investigation</b>: phase 3 explanatory studies derived from bespoke cohort study designs that sought to explain the mechanisms behind an underlying association between anticholinergic burden and cognitive decline or neuropsychiatric disturbances in people with MCI or dementia were considered to be a high level of evidence. Phase 2 explanatory studies that sought to confirm an independent association between anticholinergic burden and cognitive decline or neuropsychiatric disturbances were treated as moderate evidence; and hypothesis‐generating, phase 1 explanatory studies were treated as weak evidence for any association between anticholinergic burden and cognitive decline or neuropsychiatric disturbances. </p> <p><b>Study limitations</b>: we used the previously described QUIPS tool to evaluate the overall risk of bias of included studies. Our GRADE judgement was based upon the overall certainty of the evidence. That is, if we considered most (more than 50%) included studies to be at high risk of bias, we downgraded the evidence accordingly. </p> <p><b>Inconsistency</b>: we downgraded the evidence if associations between anticholinergic burden and cognitive decline or neuropsychiatric disturbances were heterogeneous (i.e. estimates of effect were variable across studies with regard to showing beneficial or detrimental effects, and their confidence intervals showed minimal or no overlap; the measure of the prognostic factor was highly variable; outcome measurement was highly variable; and there was methodological heterogeneity due to study design); and if the P value was low (&lt; 0.05) for the test of the null hypothesis that all studies in a meta‐analysis had the same underlying magnitude of effect. </p> <p><b>Indirectness</b>: we downgraded studies in which their investigation did not fully match with our broader review question. Specifically, if the population in the included studies only represented a subset of the population of interest (e.g. a specific subtype of dementia only), then we downgraded the evidence for the association between anticholinergic burden and cognitive decline or neuropsychiatric disturbances for indirectness. </p> <p><b>Imprecision</b>: we downgraded if the evidence was generated by few studies and a small number of participants, and most of the studies provided imprecise results; if there were insufficient numbers to meet the optimal information size in the meta‐analysis (i.e. if the total number of participants included was less than the number of participants generated by a conventional sample size calculation for a single, adequately powered study); or if the confidence intervals failed to exclude important benefit or important harm. </p> <p><b>Publication bias</b>: due to inherent issues regarding publication bias in prognostic research, we adopted the default position that publication bias was likely, and downgraded the evidence, unless our assessment of publication bias provided significant evidence to the contrary (i.e. a symmetrically distributed funnel plot, and evidence that the prognostic factor had been investigated in numerous cohort studies).  </p> <p><b>Effect size</b>: we upgraded our confidence in the effect estimate when the effect size was moderate to large (e.g. a hazard ratio of 2.5 or above).  </p> <p><b>Exposure‐response gradient</b>: we upgraded the evidence if there was an incremental increase in effect size with increasing anticholinergic burden. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015196-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015196-sec-0038"></div> <section id="CD015196-sec-0039"> <h3 class="title" id="CD015196-sec-0039">Results of the search</h3> <section id="CD015196-sec-0040"> <h4 class="title">Description of the studies</h4> <p>Our search identified a total of 18,358 records. We did not identify any additional studies by handsearching references. After de‐duplication and assessment of titles and abstracts, we evaluated 55 full‐text reports for relevance, 18 studies of which met our inclusion criteria.  Reasons for exclusion can be seen in the <a href="./references#CD015196-sec-0077" title="">Characteristics of excluded studies</a> table. <a href="#CD015196-fig-0001">Figure 1</a> shows the PRISMA flow chart.  </p> <div class="figure" id="CD015196-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD015196-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD015196-sec-0041"> <h5 class="title">Included studies</h5> <p>Seventeen studies were longitudinal cohort designs, and one used data from participants in a randomised controlled trial (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>). All studies were conducted in a retrospective manner, therefore, we were using data that were originally obtained for a purpose other than investigating the association between anticholinergic burden and adverse outcomes in a cognitively impaired older adult population.  Study sample sizes ranged from 69 to 39,107. The studies were conducted in Asia, North America, Europe, and Oceania (1 study in Korea, 1 in Thailand, 3 in the USA, 4 in UK, 1 in Ireland, 3 in Italy, 1 in Spain, 2 in Sweden, 1 in Finland, and 1 in Australia). Follow‐up times ranged from one to eight years.  </p> <p>See our <a href="./references#CD015196-sec-0076" title="">Characteristics of included studies</a> section for details. </p> </section> <section id="CD015196-sec-0042"> <h5 class="title">Participant characteristics</h5> <p>The total number of participants in all included studies was 102,684, the overwhelming majority of whom (97%) had pre‐existing cognitive impairment. Around 63% of the sample were female, and the mean or median age across studies ranged from 72 to 88 years. Ten studies recruited 87,846 participants from a population‐level database, or a mixed setting (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>); 5625 participants were from an integrative care setting (1 study, <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>); 1390 were from secondary care (3 studies: <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>); 1154 were from primary care lists (1 study, <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>); and 6669 participants were from a care‐ or nursing‐home setting (3 studies, <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>).   </p> <p>Eleven studies recruited only participants with dementia (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>). Of these, 6/11 studies were restricted to people with dementia on cholinesterase inhibitor drugs (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>); 5/11 studies were conducted in an Alzheimer’s disease‐specific population (<a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>); and 6/11 studies were conducted in a population with non‐specific dementia (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>).  Three studies were conducted in a mixed mild cognitive impairment (MCI) and dementia population (<a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>), and one study was conducted in an MCI‐only population (<a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>). Three studies were not restricted to a cognitively impaired population exclusively, but had a high proportion of cognitively impaired participants within their study sample (<a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>). Severity of cognitive impairment at baseline was variable across included studies: seven studies were conducted in a predominantly mild dementia or MCI population, or both (<a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>), while six involved a moderately or severely impaired dementia population (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>).  Severity of cognitive impairment was not reported in five studies (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>).  </p> </section> <section id="CD015196-sec-0043"> <h5 class="title">Prognostic factor</h5> <p>Anticholinergic burden was measured with five measurement tools: 12 studies used the Anticholinergic Cognitive Burden (ACB) scale (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>); three studies used the Anticholinergic Risk Scale (ARS (<a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>)); one study used the Anticholinergic Drug Scale (ADS (<a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>)); one study used the Anticholinergic Effect on Cognition (AEC) Scale (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>); and two studies used a list developed by <a href="./references#CD015196-bbs2-0086" title="TuneLE , EgeliS . Acetylcholine and delirium. Dementia and Geriatric Cognitive Disorders1999;10(5):342-4.">Tune 1999</a> (<a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>).  </p> <p>The specific anticholinergic drugs used varied between studies. Antipsychotics, such as haloperidol, quetiapine, or risperidone, were the most commonly used drugs contributing to anticholinergic burden in six studies (<a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>); two studies reported antidepressant or anxiolytic drugs as the most commonly used anticholinergic drugs (<a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>); one study reported beta blockers (Metoprolol (<a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>)), and one study reported histamine blockers as the most commonly used anticholinergic drugs (<a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>). Eight studies did not report the types of anticholinergic drugs used in their study sample in detail (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>). </p> <p>Long‐term historic or lifetime anticholinergic drug use before diagnosis of a cognitive syndrome was not recorded in any studies. The longest duration of measurement of pre‐diagnosis anticholinergic drug use was 12 months (<a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>).  </p> </section> <section id="CD015196-sec-0044"> <h5 class="title">Outcome measures</h5> <p>Nine studies assessed cognitive decline via change in score on a cognitive assessment or dementia severity, or disability rating measure (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>). Multiple studies used more than one cognitive assessment scale: seven studies used the Mini Mental State Exam (MMSE (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>)), two used the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>)), one used the Severe Impairment Battery (SIB (<a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>)), one used the Clinical Dementia Rating (CDR) scale (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>), one used the Disability Assessment for Dementia (DAD (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>)), and one study used the Cognitive Performance Scale (CPS (<a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>)).  One study assessed progression to dementia (from MCI) as an outcome, evaluated via a multi‐component assessment using standardised cut points for impairment (<a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>).  </p> <p>No studies assessed neuropsychiatric disturbances.</p> <p>Ten studies assessed mortality as an outcome; all studies used database codes or death registry records to establish mortality (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>).  </p> <p>Four studies assessed physical function or performance of activities of daily living (<a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>): one study used the Instrumental Activities of Daily Living (IADL) scale, and Physical Activities of Daily Living (PADL) scale (<a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>); one used the Katz Activities of Daily Living (ADL) scale (<a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>); one used a summary ADL score imbedded within the Resident Assessment Instrument Minimum Data Set (version 2.0) for Nursing Homes (MDS‐NH (<a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>)); and one study used the Barthel Index (BI), and Lawton and Brody Index (LBI (<a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>)).  </p> <p>Institutionalisation was assessed in one study; database claims for care in nursing homes were used as a proxy for residing in a nursing home (<a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>).  </p> </section> </section> <section id="CD015196-sec-0045"> <h4 class="title">Risk of bias in included studies</h4> <p>Risk of bias was substantial across studies: 16/18 (89%) studies were at high risk of bias in at least one domain (<a href="#CD015196-fig-0002">Figure 2</a>). The most prominent issue of concern was adjustment for covariates bias (<a href="#CD015196-fig-0003">Figure 3</a>). Nine of 18 (50%) studies did not control for severity of dementia or cognitive impairment at baseline (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>). Of the two studies investigating a cognitive outcome in a non‐specific dementia‐only population (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>), only one study controlled for type of dementia (50% (<a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>)). </p> <div class="figure" id="CD015196-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Authors' assessment of risk of bias for each domain, for each trial" data-id="CD015196-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Authors' assessment of risk of bias for each domain, for each trial</p> </div> </div> </div> <div class="figure" id="CD015196-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias for each domain, across studies" data-id="CD015196-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias for each domain, across studies</p> </div> </div> </div> <p>Additional issues of note were:</p> <p> <ul id="CD015196-list-0002"> <li> <p><b>Outcome measurement bias</b>: no studies reported blinding of investigators to outcome when scoring anticholinergic burden; only 2/18 (11%) studies reported scoring outcomes or anticholinergic burden in duplicate to minimise potential for outcome measurement bias (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>). In studies that assessed change in a cognitive outcome, 6/9 (66%) used the MMSE alone when assessing cognitive decline (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>). Four out of 6 (66%) of these were conducted in moderate to severe dementia populations, for whom floor effects are possible.  </p> </li> <li> <p><b>Reverse causation bias</b>: we judged 9/18 (50%) studies to be at high risk of bias for reverse causation (<a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>), and just 4/18 (17%) to be at low risk of bias (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>). Only 10/18 (56%) studies controlled for a covariate that could cause confounding by indication, such as urinary tract infections, mood, anxiety, or behavioural or psychological disorders (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>). </p> </li> <li> <p><b>Statistical analysis bias:</b> no studies registered a protocol outlining planned statistical analyses, and only 3/18 (17%) studies reported assessing statistical assumptions (<a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>). </p> </li> </ul> </p> </section> <section id="CD015196-sec-0046"> <h4 class="title">Associations between anticholinergic burden and clinical outcomes reported in individual studies </h4> <p>Three out of nine (33%) studies involving people with dementia reported a significantly increased risk of greater long‐term cognitive decline for participants with an anticholinergic burden, compared to participants with no or minimal anticholinergic burden: one of these studies reported the association to be independent of core variables (age, sex, comorbidities, and use of anticholinesterase inhibitors (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>)); one study reported the association was independent of age, sex, and time (<a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>); and one study reported univariable association only (<a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>). Five out of nine (56%) studies reported no significant difference in risk of long‐term cognitive decline between those with an anticholinergic burden and those with no or minimal burden (<a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>), while one study reported that cognition significantly improved for those with the highest anticholinergic burden in the initial six months post‐dementia diagnosis, before demonstrating similar slopes of decline to those with no or lower burden for the remaining 6 to 36 months (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>). Of three studies conducted in a population with mild dementia (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>, <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>, <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a>), 2/3 (67%) reported a significant association between anticholinergic burden and reduced long‐term cognition (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>), compared to one out of five (20% (<a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>)), which investigated this association in a moderately or severely impaired population (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>).  </p> <p>One study evaluated the progression from MCI to dementia, and reported a significantly increased risk for those with an anticholinergic burden compared to those with no burden, based on anticholinergic burden defined by the ARS (<a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>). This association was independent of age, sex, education level, baseline instrumental activities of daily living (IADL), diabetes, and cardiovascular diseases.  </p> <p>Six out of 10 studies (60%) reported a significantly increased risk of mortality. One study reported a significantly increased risk for those with a high anticholinergic burden relative to those with mild or no burden (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>); one reported an increased risk for those with at least moderate anticholinergic burden compared to those with no anticholinergic burden (<a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>); three reported significant differences for any anticholinergic burden versus no burden (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>); and one study reported significant differences for users of antipsychotic anticholinergic drugs versus non‐users of antipsychotic anticholinergic drugs, specifically (<a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>).  All significant associations were adjusted for covariates; however only 4/6 studies controlled for all core covariates (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>). Three out of four studies (75%) that failed to find an association with mortality were conducted in a nursing home setting that included non‐cognitively impaired individuals (<a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>).  </p> <p>One out of four studies (25%) reported a significantly increased risk of reduced physical function for people with an anticholinergic burden compared to people with no burden (<a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>). This association was independent of core covariates, but was conducted in a nursing home population that included non‐cognitively impaired individuals.  </p> <p>One study investigated the risk of institutionalisation for moderate to severe anticholinergic drug users versus no or low anticholinergic drug users. <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a> did not observe a significant difference between groups after adjusting for age, sex, and comorbidities; however, they did not control for baseline severity of dementia.  </p> </section> <section id="CD015196-sec-0047"> <h4 class="title">Variables that moderated the observed association with the outcome</h4> <p>There was observable alteration of results based upon within‐study variables. </p> <p>One study reported different results based on method for assessing outcome (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>). Specifically, they observed a significant association between anticholinergic burden and cognitive decline when they used the CDR and DAD scales to assess cognition, but observed no association between anticholinergic burden and ADAS‐cog scores.  </p> <p>One study observed variability based on type of dementia (<a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>). Specifically, they observed a significantly increased risk association between anticholinergic burden and the composite outcome of mortality and stroke, for participants with Alzheimer’s disease and unspecified dementia; they observed no association for those with mixed dementia, vascular dementia, dementia with Lewy bodies, Parkinson’s disease dementia, frontotemporal dementia, or ‘other dementia’. </p> <p>One study reported APOe4 allele status moderated the association between anticholinergic burden and cognition (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>). The association between ACB and CDR‐defined dementia severity was only significant when the ACB interaction with APOe4 allele status was included in the analysis.  </p> <p>The scale used to measure anticholinergic burden altered results in one study. <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a> found that progression to dementia was only predicted by the ARS scale, not by the ACB scale. </p> <p>Four studies investigated the effect of drug type and class on association; results were highly heterogeneous. <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a> found that respiratory, urological, and 'other' anticholinergic drugs were associated with an increased risk of mortality, but antipsychotics, antidepressants, antiparkinsonian, gastrointestinal, and antihistamine drugs were not.  <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a> found that only antipsychotic anticholinergic drugs were associated with increased risk of mortality, but they observed no association for tricyclic antidepressants or ‘other’ anticholinergic drugs. <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a> found no association between anticholinergics and mortality risk in general, but the use of anticholinergic drugs targeting the bladder was associated with a reduced mortality risk. By contrast, <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a> found no significant class‐based effect on cognition for any individually investigated anticholinergic drug type (specifically, antidepressants, neuroleptics, and bladder antimuscarinics).  </p> <p>Six studies examined the effects of severity of anticholinergic burden on outcome significance (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>; <a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>). <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a> reported that a baseline ACB ≥ 2 was significantly associated with death, whereas a baseline ACB of 1 was not. No other studies reported variation in the significance of association when stratifying by severity of anticholinergic burden.  </p> <p>One study reported that the association between anticholinergic burden and mortality or hospitalisation (analysed as a composite outcome) was only present in those with coronary artery disease (<a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>).  </p> </section> <section id="CD015196-sec-0048"> <h4 class="title">Meta‐analysis</h4> <p>We considered that the studies were too heterogeneous to pool data for all cognitive outcomes—particularly in relation to the control for minimum core covariates, and the method for assessing outcome. There were no studies from which we could pool data for neuropsychiatric disturbance outcomes, and insufficient data to pool for physical function and institutionalisation outcomes.  </p> <p>We extracted mortality‐based hazard ratio data directly from seven studies (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>); we were able to obtain data for one additional study after contacting the authors (<a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>). Sufficient data for this outcome were only available for fully adjusted multivariable analysis. Two studies did not adjust for the minimum variables (age, sex, and comorbidities), and hence, we excluded them from the analysis (<a href="./references#CD015196-bbs2-0010" title="KumpulaEK , BellJS , SoiniH , PitkäläKH . Anticholinergic drug use and mortality among residents of long‐term care facilities: a prospective cohort study. Journal of Clinical Pharmacology2011;51(2):256-63. [PMID: 20489026]">Kumpula 2011</a>; <a href="./references#CD015196-bbs2-0014" title="McMichaelAJ , ZafeiridiE , RyanM , CunninghamEL , PassmoreAP , McGuinnessB . Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging &amp; Mental Health2021;25(8):1475-82. [PMID: 33073601]">McMichael 2021</a>).  </p> <p>The primary analysis was restricted to four studies that measured anticholinergic burden using the ACB scale (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>). Results suggest that cognitively impaired people with a high ACB score (≥ 3), may have an increased risk of mortality compared to those with no or low ACB scores (hazard ratio (HR) 1.153, 95% confidence interval (CI) 1.030 to 1.292; 4 studies, 48,663 participants; <a href="#CD015196-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD015196-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, measured by the Anticholinergic Cognitive Burden scale." data-id="CD015196-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, measured by the Anticholinergic Cognitive Burden scale. </p> </div> </div> </div> <p>As an exploratory analysis, we also examined the association with mortality regardless of anticholinergic measurement scale used. We included data from six studies (<a href="./references#CD015196-bbs2-0001" title="AhYM , SuhY , JunK , HwangS , LeeJY . Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic &amp; Clinical Pharmacology &amp; Toxicology2019;124(6):741-8. [PMID: 30511428]">Ah 2019</a>; <a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0004" title="BoudreauDM , YuO , GraySL , RaebelMA , JohnsonJ , LarsonEB . Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. The American Journal of Geriatric Psychiatry2011;59(11):2069-76. [PMID: 22091958]">Boudreau 2011</a>; <a href="./references#CD015196-bbs2-0005" title="CrossAJ , GeorgeJ , WoodwardMC , AmesD , BrodatyH , WolfeR , ConnorsMH , ElliottRA . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis2017;60(2):349-358. [PMID: 28869467]">Cross 2017</a>; <a href="./references#CD015196-bbs2-0015" title="Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open2019;9:e026171. [PMID: 31092652]">Porter 2019</a>; <a href="./references#CD015196-bbs2-0016" title="TanECK , EriksdotterM , Garcia-PtacekS , FastbomJ , JohnellK . Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease2018;65(2):589-96. [PMID: 30056424]">Tan 2018</a>). Results were consistent with our primary analysis, suggesting that regardless of the scale used to measure anticholinergic burden, those with a high anticholinergic burden may be at increased risk of mortality compared to those with no or minimal burden (HR 1.102, 95% CI 1.044 to 1.163; 6 studies, 68,381 participants; <a href="#CD015196-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD015196-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, regardless of scale used to measure anticholinergic burden." data-id="CD015196-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, regardless of scale used to measure anticholinergic burden. </p> </div> </div> </div> <p>We were unable to formally investigate the possibility of publication or small study bias by generating a funnel plot due to limited study numbers. However, risk of publication bias is assumed within this field. </p> <p>There were insufficient data to explore the relationship between anticholinergic burden and mortality at different levels of anticholinergic severity.  Similarly, there were insufficient data to conduct any planned subgroup analyses, or meta‐regression. There were also insufficient data to pool from any other secondary outcomes (see <a href="#CD015196-sec-0074">Differences between protocol and review</a>).  </p> </section> <section id="CD015196-sec-0049"> <h4 class="title">Certainty of the evidence (GRADE)</h4> <p>The overall certainty of the evidence for the primary outcome of cognitive decline was very low. Evidence was downgraded for risk of bias, inconsistency, indirectness, and publication bias.  </p> <p>We had low or very low confidence in the evidence for all secondary outcomes. For mortality, we considered the evidence to be of low certainty, downgraded due to risk of bias and presumed publication bias. For physical function, we considered the evidence to be of very low certainty, downgraded for risk of bias, inconsistency, indirectness, imprecision, and publication bias. For institutionalisation, we also considered the evidence to be of very low certainty, downgraded for risk of bias, indirectness, imprecision, and publication bias (see <a href="./appendices#CD015196-sec-0067">Appendix 6</a>). </p> <section id="CD015196-sec-0050"> <h5 class="title">Comparison of scales</h5> <p>There were too few studies to conduct a network meta‐analysis to examine comparative prognostic validity of different anticholinergic burden measurement scales. Only one study directly compared scales within a single sample (<a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>). Results of this study suggested that the ARS may have greater prognostic ability than the ACB scale for predicting progression from MCI to dementia; however, statistical power was severely limited due to a short (1 year) follow‐up, and only 14 participants with dementia.  </p> <p>Of the individual anticholinergic scales used in the literature, 2/6 (33%) studies that used the ACB scale found a significant association with cognitive decline (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>). A single study that used the AEC scale reported mixed results for the association with cognitive decline (<a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>). Of the two studies that used the ARS (<a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>), 1/2 (50%) found a significant association with cognitive decline (<a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>). No studies investigated cognitive decline or neuropsychiatric outcomes using the ADS; and 1/2 (50%) of the studies that investigated the association with cognitive decline using the <a href="./references#CD015196-bbs2-0086" title="TuneLE , EgeliS . Acetylcholine and delirium. Dementia and Geriatric Cognitive Disorders1999;10(5):342-4.">Tune 1999</a> list found a significant association (<a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015196-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015196-sec-0051"></div> <section id="CD015196-sec-0052"> <h3 class="title" id="CD015196-sec-0052">waSummary of main results</h3> <p>The evidence pertaining to the association between anticholinergic burden and long‐term cognitive decline in older adults with pre‐existing cognitive impairment is inconclusive. Results are highly inconsistent. Most studies do not support an association. Examination of the relationship between the anticholinergic burden and secondary outcomes that we would expect to co‐occur with declining cognition, do not generally support an important effect either. There was no evidence that anticholinergic burden increases the risk of institutionalisation, and most studies failed to find any association with decline in physical function. There is also an absence of any evidence to determine whether anticholinergic burden is a prognostic factor for long‐term neuropsychiatric outcomes. </p> <p>Increased risk of death is the adverse outcome most consistently associated with anticholinergic burden in a cognitively impaired population. The majority of studies (6/10) included in our review found a significant association with an increased risk of mortality. This is further supported by our meta‐analysis, which suggests an increase in risk of around 15% for those with a high anticholinergic burden.  </p> <p>The relative ability of different anticholinergic burden scales to predict adverse clinical outcomes in a cognitively impaired population cannot yet be established. Although there is evidence from one study that the Anticholinergic Risk Scale (ARS) may be more capable than the Anticholinergic Cognitive Burden (ACB) scale of predicting future dementia onset in a mild cognitive impairment (MCI) population, the limitations of the study make this result highly uncertain (<a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>). The ACB scale was the most widely used of the anticholinergic burden tools; however, the lack of consistent associations with cognitive outcomes observed for this tool make its prognostic value for predicting cognitive decline in a dementia population questionable. Moreover, some of the most commonly used drugs (e.g. beta blockers (e.g. Metoprolol) and histamine blockers) have a dubious ability to contribute to overall anticholinergic burden according to first‐principle pharmacology. Hence, the predictive ability of anticholinergic burden scales at the level of the individual may vary considerably, depending on the relative contribution of specific drug types to the assigned anticholinergic burden score. </p> </section> <section id="CD015196-sec-0053"> <h3 class="title" id="CD015196-sec-0053">Overall completeness and applicability of evidence</h3> <p>Most studies were conducted at a population level or in mixed settings, therefore, our results are most applicable at a population level, rather than any individual setting. Currently, there is a lack of evidence to determine whether different anticholinergic burden scales perform differently across settings. </p> <p>While this topic was investigated in a range of geographic locations, no studies have been conducted in the Middle East, South America, or Africa. The ability of anticholinergic scales to predict adverse clinical outcomes may vary by country, due to differences in routine prescribing practice. Drugs with anticholinergic properties that are prescribed in some countries may not be prescribed in the country where a scale was developed and validated. On this basis, we cannot be sure that our results will generalise globally, and it is important that evaluations of anticholinergic burden scales are conducted in other regions.  </p> </section> <section id="CD015196-sec-0054"> <h3 class="title" id="CD015196-sec-0054">Certainty of evidence</h3> <p>There were major issues with study quality that weakened the certainty of our evidence. Using GRADE, we evaluated the certainty of the evidence as low or very low for all outcomes. Study risk of bias was a particularly significant concern. Most studies had a relatively short follow‐up that may have limited their ability to observe associations. The Mini Mental State Examination (MMSE) was the most commonly used tool for assessing cognitive outcomes, yet, it may lack the sensitivity to measure change in some cognitive domains, and has the potential for floor effects in more severely impaired populations (<a href="./references#CD015196-bbs2-0063" title="HerrmannN , GauthierS , LysyPG . Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's &amp; Dementia2007;3(4):385-97. [PMID: 19595959]">Herrmann 2007</a>). Many studies did not control for key variables, and despite regular reports that antipsychotics were the most widely used anticholinergic medication, control for confounding by indication was frequently lacking. As some anticholinergic drugs may be prescribed in response to increasing severity of dementia, many observed associations between anticholinergic burden and clinical outcomes could be driven by between‐group differences in severity of dementia, wherever this was not controlled for.  </p> </section> <section id="CD015196-sec-0055"> <h3 class="title" id="CD015196-sec-0055">Limitations of the review process</h3> <p>We attempted to minimise bias in the review process by conducting study selection, data extraction, and risk of bias assessment in duplicate. We followed the recommended guidance for design, reporting, and statistical analysis, and adapted previously used assessment forms to improve compatibility with this topic. Despite this, there were several limitations of note. </p> <p>The major limitation of our review was the lack and heterogeneity of data for several outcomes, including variation in the measurement of cognitive decline and physical function. This prevented us from drawing firm conclusions for our main objectives, and conducting our planned subgroup analyses.  </p> <p>Although we were able to minimise issues of heterogeneity in our meta‐analysis, there was still variability in numerous study characteristics, including the point of dichotomisation used on the anticholinergic burden scale, and the type of comparison used in different studies (e.g. comparing any burden to no burden versus comparing high burden to minimal burden). This affected the degree of nuance we were able to provide for the associations. In addition, there was one study that reported no significant association between anticholinergic burden and mortality, which we were unable to include in our meta‐analysis due to lack of hazard ratio data (<a href="./references#CD015196-bbs2-0018" title="VetranoDL , La CarpiaD , GrandeG , CasucciP , BacelliT , BernabeiR , et al, Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. Journal of the American Medical Directors Association2016;17(11):1056-9. [PMID: 27590402]">Vetrano 2016</a>). This may have biased our meta‐analysis towards a significant effect. </p> <p>Lastly, publication bias is a general concern within this literature, and we did not include grey literature in our review, which may have exacerbated this problem.  </p> </section> <section id="CD015196-sec-0056"> <h3 class="title" id="CD015196-sec-0056">Agreements and disagreements with other studies or reviews</h3> <p>The lack of a consistent association between anticholinergic burden and cognitive outcomes conflicts with the findings of our companion review that examined the association in cognitively healthy older adults (<a href="./references#CD015196-bbs2-0085" title="Taylor-RowanM , EdwardsS , Noel-StorrAH , McCleeryJ , MyintPK , SoizaR , et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013540. [DOI: 10.1002/14651858.CD013540.pub2]">Taylor‐Rowan 2021</a>). It is possible that a significant deterioration of the cholinergic system in dementia limits the adverse impact of anticholinergic drugs on cognition. By extension, this may suggest that the severity of pre‐existing impairment is crucial to the prognostic relationship in the dementia population (<a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>). In support of this, the majority (2/3) of studies that investigated the association in people with mild dementia or cognitive impairment found a significant deleterious effect associated with anticholinergic burden; this contrasts with just one in five of the studies that investigated the association in people with moderate to severe dementia. However, various study limitations and differences in methodology may also contribute to these different results. Therefore, a possible association with severity of baseline cognitive impairment requires further investigation. </p> <p>Our results are broadly consistent with a recently published review that reported inconclusive findings for the association between anticholinergic burden and cognitive decline in a dementia population (<a href="./references#CD015196-bbs2-0088" title="WangK , AlanJ , PageAT , DimopolousE , Etherton-BeerC . Anticholinergics and clinical outcomes amongst people with pre-existing dementia: a systematic review. Maturitas2021;151:1-14.">Wang 2021</a>). That review found highly consistent reports of increased mortality risk for anticholinergic users.  Our review builds upon these prior findings by presenting a more comprehensive depiction of the available prognostic literature. We also found the association between anticholinergic burden and mortality to be less homogenous than was previously suggested, and we provided an adjusted hazard ratio summary figure of the possible increased risk of mortality.    </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015196-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/urn:x-wiley:14651858:media:CD015196:CD015196-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD015196-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_t/tCD015196-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015196-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/urn:x-wiley:14651858:media:CD015196:CD015196-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Authors' assessment of risk of bias for each domain, for each trial" data-id="CD015196-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_t/tCD015196-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Authors' assessment of risk of bias for each domain, for each trial</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015196-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/urn:x-wiley:14651858:media:CD015196:CD015196-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias for each domain, across studies" data-id="CD015196-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_t/tCD015196-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias for each domain, across studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015196-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/urn:x-wiley:14651858:media:CD015196:CD015196-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, measured by the Anticholinergic Cognitive Burden scale." data-id="CD015196-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_t/tCD015196-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, measured by the Anticholinergic Cognitive Burden scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015196-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/urn:x-wiley:14651858:media:CD015196:CD015196-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, regardless of scale used to measure anticholinergic burden." data-id="CD015196-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_t/tCD015196-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Relative mortality risk of those with a high anticholinergic burden vs those with minimal/no anticholinergic burden, regardless of scale used to measure anticholinergic burden. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/media/CDSR/CD015196/image_n/nCD015196-FIG-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015196-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>‐Risk of cognitive decline or neuropsychiatric outcomes in people with dementia for those with an anticholinergic burden compared to those with no or minimal anticholinergic burden</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> older adults with cognitive impairment at baseline </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention:</b> anticholinergic burden </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Comparison:</b> no or minimal anticholinergic burden </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcomes:</b> cognitive decline (multi‐domain) or neuropsychiatric disturbances </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Timing:</b> prognostic factors measured at baseline; outcomes obtained at a minimum of 1‐month follow‐up via longitudinal, observational cohort or case‐control study design </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Setting:</b> mixed (care homes, community, hospitals) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Relative effect (95%CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>No. of participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive decline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18213</p> <p>(10)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝  </p> <p>Very low<sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies were too heterogeneous to pool.  The majority of studies did not identify a significantly increased risk for those with an anticholinergic burden compared to those with no or minimal burden.  However, the inconsistency and high risk of bias of the available evidence means no firm conclusions can be drawn.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies assessed this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>AChEI:</b> acetylcholinesterase inhibitor; <b>CI:</b> confidence interval; <b>NA:</b> not applicable </p> <p><b>GRADE Working Group grades of evidence </b> </p> <p><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect </p> <p><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate </p> <p><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate </p> <p><b>Very low certainty:</b> we are very uncertain about the estimate </p> <p><sup>a</sup><a href="./references#CD015196-bbs2-0002" title="BisharaD , PereraG , HarwoodD , TaylorD , SauerJ , StewartR , et al. The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry2020;35(9):1069-77. [DOI: 10.1002/gps.5330]">Bishara 2020</a>; <a href="./references#CD015196-bbs2-0003" title="BottiggiKA , SalazarJC , YuL , Caban-HoltAM , RyanM , SchmittFA . Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal of Geriatric Psychiatry2007;15(4):357-9. [DOI: 10.1097/JGP.0b013e31802dd354]">Bottiggi 2007</a>; <a href="./references#CD015196-bbs2-0006" title="DyerAH , MurphyC , SeguradoR , LawlorB , KennellySP , NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease?The Journals of Gerontology: Series A2020;75(5):987-94. [PMID: 31613323]">Dyer 2020</a>; <a href="./references#CD015196-bbs2-0007" title="FoxC , LivingstonG , MaidmentID , CoultonS , SmithardDG , BoustaniM , et al. The impact of anticholinergic burden in Alzheimer's dementia − the LASER-AD study. Age and Ageing2011;40(6):730-5. [PMID: 21926432]">Fox 2011</a>; <a href="./references#CD015196-bbs2-0008" title="HaaksmaML , RizzutoD , LeoutsakosJS , MarengoniA , TanECK , Olde RikkertMGM , et al. Predicting cognitive and functional trajectories in people with late-onset dementia: 2 population-based studies. Journal of the American Medical Directors Association2019;20(11):1444-50. [PMID: 31109912]">Haaksma 2019</a>; <a href="./references#CD015196-bbs2-0011" title="LandiF , Dell'AquilaG , CollamatiA , MartoneAM , ZulianiG , GasperiniB , et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the American Medical Directors Association2014;15(11):825-9. [PMID: 25282629]">Landi 2014</a>; <a href="./references#CD015196-bbs2-0013" title="LuCJ , TuneLE . Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(4):458-61. [PMID: 12837675]">Lu 2003</a>; <a href="./references#CD015196-bbs2-0017" title="TrevisanC , LimongiF , SivieroP , NoaleM , CignarellaA , ManzatoE , et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research2021;33(1):49-56. [PMID: 31758500]">Trevisan 2021</a>; <a href="./references#CD015196-bbs2-0009" title="JenraumjitR , ChinwongS , ChinwongD , KanjanarachT , KshetradatT , WongpakaranT , et al. Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study. BMC Research Notes2020;13(1):4. [PMID: PMC6941288]">Jenraumjit 2020</a>; <a href="./references#CD015196-bbs2-0012" title="López-MatonsN , Conill BadellD , Obrero CusidóG , Gil SaladiéD , Padrós SelmaJ , Martin-LópezA . Anticholinergic drugs and cognitive impairment in the elderly. Medicina Clínica (English Edition)2018;151(4):141-4. [PMID: 29525116]">Lopez‐Matons 2018</a><br/><sup>b</sup>Most studies were at high risk of bias; downgraded 2 levels<br/><sup>c</sup>Results and measurement methods across studies werehighly heterogeneous; downgraded 2 levels<br/><sup>d</sup>Most studies conducted in Alzheimer disease population only, or dementia population who were also on AChEIs; downgraded 2 levels<br/><sup>e</sup>We were unable to formally investigate publication bias via a funnel plot; however, publication bias is assumed within this literature; downgraded 1 level </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015196-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient/Problem; Intervention; Comparison; Outcome; Timing (PICOTS)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Older adults (mean age ≥ 50 years) with prior cognitive impairment, MCI, dementia, or AChE use at baseline </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic burden, measured by any validated ordinal anticholinergic burden scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator prognostic factors (covariates of interest)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age, sex, comorbidity, and AChE use</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive decline (multidomain) or neuropsychiatric disturbances</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Timing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prognostic factors should be measured at baseline. Outcomes should be obtained at a minimum of 1‐month follow‐up via longitudinal, observational cohort/case‐control study design </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruitment from primary, secondary, or community, or care‐home settings</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>AChE: anticholinesterase inhibitor</p> <p>MCI: mild cognitive impairment</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient/Problem; Intervention; Comparison; Outcome; Timing (PICOTS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015196.pub2/full#CD015196-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015196.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD015196-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015196-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015196-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015196-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD015196-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD015196-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015196-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD015196-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015196-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015196-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015196\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015196\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015196\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015196\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015196\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015196.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015196.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015196.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015196.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015196.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718019507"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015196.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718019511"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015196.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc618af72f49c',t:'MTc0MDcxODAxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 